

PHARMACY POLICY STATEMENT

Marketplace

DRUG NAME	Oral Prostacyclins for Pulmonary Arterial Hypertension: Orenitram (treprostinil extended-release), Uptravi (selexipag tablets)
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Pulmonary Arterial Hypertension (PAH) is a rare but serious condition characterized by elevated pulmonary arterial resistance. Orenitram and Uptravi are approved for the treatment of PAH World Health Organization (WHO) Group 1. Orenitram is indicated to delay disease progression and to improve exercise capacity. Uptravi is approved to delay disease progression and reduce the risk of hospitalization for PAH.

Oral Prostacyclins will be considered for coverage when the following criteria are met:

Pulmonary Arterial Hypertension [WHO Group 1]

For **initial** authorization: 0675 re W* nQ526.28 1 73.ioP -m 030q 49. Q q 0 1 287.58 366.77 Tm 0 G [(o)-

1. Member is at least 18 years of age or older; AND
2. Medication must be prescribed by or in consultation with a cardiologist or pulmonologist; AND
3. Member must have a diagnosis of WHO Group 1 PAH confirmed by right heart catheterization; AND
4. Member must have documentation of **one** of the following:
 - a) Patient had an acute response to vasodilator testing AND has tried a calcium channel blocker (CCB) for at least 3 months;
 - b) Patient did not have a response to vasodilator testing;
 - c) Patient cannot undergo vasodilator testing;
 - d) Patient cannot take CCB therapy; AND
5. Member has tried and failed an inhaled or injectable prostacyclin; AND
6. Member has tried and failed **one** of the following oral medications: phosphodiesterase type 5 inhibitor (ie. Sildenafil, Tadalafil), endothelin receptor antagonist (ie. Ambrisentan, Bosentan, Macitentan), or Soluble Guanylate Cyclase Stimulator (ie. Adempas); OR
7. Member has WHO functional class III symptoms with rapid progression of disease (see appendix); OR
- 8.



CareSource considers Oral Prostacyclins